Emicizumab
BLOOD AND BLOOD FORMING ORGANS
Also known as: ACE910, emicizumab (genetical recombination), emicizumab-kxwh, hemlibra
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Emicizumab is a drug catalogued in DrugCentral. It was first approved by the FDA in 2017. DrugCentral lists 2 molecular targets, including F9 and F10. Recorded indications include Hereditary factor VIII deficiency disease.
- Molecular targets: F9 and F10 (2 listed in DrugCentral).
- Indications: Hereditary factor VIII deficiency disease.
- ATC code: B02BX06 (Other systemic hemostatics).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Hereditary factor VIII deficiency disease
Mechanism & targets
Molecular targets (2)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Coagulation factor IX | F9 | other | Kd 5.80 |
| Coagulation factor X | F10 | other | Kd 5.73 |
Regulatory approvals (3)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2018-03-23 | PMDA | — | Chugai Pharmaceutical Co., Ltd. | |
| 2018-02-23 | EMA | — | Roche Registration Limited | |
| 2017-11-16 | FDA | — | GENENTECH INC | Yes |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
B02BX06 | BLOOD AND BLOOD FORMING ORGANS › ANTIHEMORRHAGICS › VITAMIN K AND OTHER HEMOSTATICS › Other systemic hemostatics |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Haemorrhage | 2871.0 |
| Haemarthrosis | 2156.3 |
| No adverse event | 1806.9 |
| Muscle haemorrhage | 536.8 |
| Traumatic haemorrhage | 461.0 |
| Off label use | 358.5 |
| Activated partial thromboplastin time prolonged | 228.9 |
| Spontaneous haemorrhage | 205.8 |
| Drug specific antibody present | 190.1 |
| Anti factor VIII antibody positive | 189.2 |
| Haematoma | 181.3 |
| Head injury | 179.9 |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | 1610943-06-0 |
| InChIKey | — |
| PubChem CID | — |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Emicizumab used for?
DrugCentral lists the following indications for Emicizumab: Hereditary factor VIII deficiency disease.
How does Emicizumab work?
Its molecular targets in DrugCentral include F9 and F10.
When was Emicizumab first approved?
Emicizumab was first approved by the FDA in 2017.
Browse: all drugs starting with E · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5268 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL3833393 — compound record and bioactivity
- DrugBank DB13923 — drug record
- FDA UNII 7NL2E3F6K3 — substance identity
- DailyMed: FDA labels for Emicizumab — current prescribing information (label search)
- UniProt P00740 (F9) — target protein
- UniProt P00742 (F10) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.